AI partners with liquid biopsy for ‘robust’ identification of women with ovarian cancer
An artificial intelligence-driven algorithm used a novel liquid biopsy assay to differentiate women with ovarian cancer from healthy patients, according to results presented at American Association for Cancer Research Annual Meeting.The analysis of cell-free DNA and specific protein biomarkers produced sensitivity rates ranging from 69% to 100% for stage I to stage IV ovarian cancer.